Kraig Biocraft Laboratories, Inc. Announces Stock Dividend

EAST LANSING, Mich., March 24, 2009 (GLOBE NEWSWIRE) -- Kraig Biocraft
Laboratories, Inc. (OTCBB:KBLB) today announced that its Board of Directors has
approved a stock dividend. The Board declared that shareholders of record as of
the close of business on the record date will be issued nine additional shares
for each share of Common Stock held.

"This stock dividend is intended to lay the groundwork for the growth of the
Company," said CEO Kim K. Thompson. "It is part of our ongoing efforts to
improve trading liquidity, broaden ownership, promote capital investment and
enhance shareholder value. This action is enabled by the Company's continued
success in the laboratory and is consistent with the Board's commitment to take
actions designed to create a wider distribution of the Company's stock."

The Board has directed the Company's officers to confer with market oversight
authorities and its transfer agents as soon as is practical to determine a
record date.

Kraig is a biotechnology company working to develop and commercialize high
performance polymers using spider silk gene sequences. The company hopes to tap
into the $92 billion market for high performance and technical fibers. The
Company works in cooperation with leading universities and university
researchers. In 2007, Kraig Biocraft Laboratories signed an intellectual
property and collaborative research agreement with the University of Notre Dame.
Since that time, the Company has been a proud sponsor of genetic research within
the University.

For more information on Kraig Biocraft Laboratories, and to hear an audio
interview with Kraig's CEO, please visit the Company's web site:
www.KraigLabs.com

The Kraig Biocraft Laboratories, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4817

This press release includes certain statements that may be deemed to be
"forward-looking statements" within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. All statements included in this press release, other than statements
of historical facts, address matters that the company reasonably expects,
believes or anticipates will or may occur in the future. These statements are
made on the basis of management's current views and assumptions. As a result,
there can be no assurance that management's expectations will necessarily come
to pass. Such statements are subject to various assumptions, risks and
uncertainties. Investors are cautioned that any such statements are not
guarantees of future performance and that actual results or developments may
differ materially from those described in the forward-looking statements.

-0-
CONTACT: Kraig Biocraft Laboratories, Inc.
Kim K. Thompson, CEO
(517) 336-0807
info@KraigLabs.com